Trial Profile
A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Apr 2017 Status changed from not yet recruiting to completed.
- 05 May 2010 Planned initiation date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov record.
- 17 Feb 2009 New trial record